Before you vaccinate ask:
- Does my child really need this vaccination?
- Is my child well enough to have this vaccine?
- Has my child had a bad reaction to a vaccination before?
- Does my child or family have a history of:
Vaccine reactions? Convulsions? Neurological disorders?
Allergies (asthma, antibiotics)? Immune system problems? - Do I have full information on the vaccine's side effects?
- Do I know how to identify a vaccine reaction?
- Do I know how and why my doctor should report a vaccine reaction?
- Do I know the vaccine's name and batch number?
- Do I know what chemicals and biological agents are in the vaccine?
- Make informed vaccine decisions and help prevent vaccine reactions!
Sanofi Pasteur Fluzone Quadrivalent Influenza Virus Vaccine Quadrivalent Types A and B (Split Virion)
http://www.sanofipasteur.ca/sites/default/files/sites/default/files/pictures/Fluzone_QIV_E_2017.pdf
PubMed:
http://www.ncbi.nlm.nih.gov/pubmed/11500788#
A 12-month follow-up of an influenza vaccination campaign based on voluntary adherence: report on upper-respiratory symptoms among volunteers and non-volunteers.
Ramadan PA, de Araújo FB, Ferreira Júnior M.
Source
Department of Clinical Medicine, Faculty of Medicine, Universidade de São Paulo, São Paulo, Brazil.
'..Conclusions: The making of previous reference to repetitive upper-respiratory infections was a major difference between those who accepted or rejected the vaccine. The vaccination itself was not sufficient to reduce the number of occurrences of respiratory symptoms and related absenteeism to levels similar to those found among non-vaccinated people....'
The Cochrane Library 7th July 2010
Vaccines for preventing influenza in healthy adults
Tom Jefferson, Carlo Di Pietrantonj,Alessabdro Rivetti, Ghada A Bawazeer, Lubna A Al-Ansary, Eliana Ferroni
'...Plain language summary
Vaccines to prevent influenza in healthy adults
Over 200 viruses cause influenza andinfluenza-like illness which produce the same symptoms (fever, headache, aches and pains, cough and runny noses). Without laboratory tests, doctors cannot tell the two illnesses apart. Both last for days and rarely lead to death or serious illness. At best, vaccines might be effective against only influenza A and B, which represent about 10% of all circulating viruses. Each year, the World Health Organization recommends which viral strains should be included in vaccinations for the forthcoming season.
Authors of this review assessed all trials that compared vaccinated people with unvaccinated people. The combined results of these trials showed that under ideal conditions (vaccine completely matching circulating viral configuration) 33 healthy adults need to be vaccinated to avoid one set of influenza symptoms. In average conditions (partially matching vaccine) 100 people need to be vaccinated to avoid one set of influenza symptoms. Vaccine use did not affect the number of people hospitalised or working days lost but caused one case of Guillian-Barré syndrome (a major neurological condition leading to paralysis) for every one million vaccinations. Fifteen of the 36 trials were funded by vaccine companies and four had no funding declaration. Our results may be an optimistic estimate because company-sponsored influenza vaccines trials tend to produce results favorable to their products and some of the evidence comes from trials carried out in ideal viral circulation and matching conditions and because the harms evidence base is limited.....'
The American Journal of Clinical Nutrition 11th February 2010
http://ajcn.nutrition.org/content/early/2010/03/10/ajcn.2009.29094.abstract
Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren
Mitsuyoshi Urashima, Takaaki Segawa, Minoru Okazaki, Mana Kurihara,Yasuyuki Wada, and Hiroyuki Ida
'..Objective: We investigated the effect of vitamin D supplements on the incidence of seasonal influenza A in schoolchildren...'
'..Conclusion: This study suggests that vitamin D3 supplementation during the winter may reduce the incidence of influenza A, especially in specific subgroups of schoolchildren. This trial was registered at https://center.umin.ac.jp as UMIN000001373..'